JP2004528332A5 - - Google Patents

Download PDF

Info

Publication number
JP2004528332A5
JP2004528332A5 JP2002582954A JP2002582954A JP2004528332A5 JP 2004528332 A5 JP2004528332 A5 JP 2004528332A5 JP 2002582954 A JP2002582954 A JP 2002582954A JP 2002582954 A JP2002582954 A JP 2002582954A JP 2004528332 A5 JP2004528332 A5 JP 2004528332A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
polymer
uric acid
crosslinking agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002582954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/011492 external-priority patent/WO2002085381A1/en
Publication of JP2004528332A publication Critical patent/JP2004528332A/ja
Publication of JP2004528332A5 publication Critical patent/JP2004528332A5/ja
Pending legal-status Critical Current

Links

JP2002582954A 2001-04-18 2002-04-10 痛風を治療する方法および尿酸を結合する方法 Pending JP2004528332A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
US30556701P 2001-07-13 2001-07-13
PCT/US2002/011492 WO2002085381A1 (en) 2001-04-18 2002-04-10 Method for treating gout and binding uric acid

Publications (2)

Publication Number Publication Date
JP2004528332A JP2004528332A (ja) 2004-09-16
JP2004528332A5 true JP2004528332A5 (enExample) 2005-12-22

Family

ID=26962624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002582954A Pending JP2004528332A (ja) 2001-04-18 2002-04-10 痛風を治療する方法および尿酸を結合する方法

Country Status (9)

Country Link
US (2) US20030039627A1 (enExample)
EP (1) EP1416942B1 (enExample)
JP (1) JP2004528332A (enExample)
AT (1) ATE380553T1 (enExample)
BR (1) BR0209133A (enExample)
CA (1) CA2444347A1 (enExample)
DE (1) DE60224052T2 (enExample)
MX (1) MXPA03009571A (enExample)
WO (1) WO2002085381A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
WO2004099288A1 (en) * 2003-05-09 2004-11-18 Carlsberg A/S Polyethyleneimine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
CA2607953A1 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
WO2007027566A2 (en) * 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
CA2622693C (en) 2005-09-15 2015-05-05 Genzyme Corporation Sachet formulation for amine polymers
JP2009514966A (ja) * 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
WO2007130463A2 (en) * 2006-05-05 2007-11-15 Genzyme Corporation Amine condensation polymers as phosphate sequestrants
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
WO2008011047A2 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EP2114376A1 (en) * 2007-02-23 2009-11-11 Genzyme Corporation Amine polymer compositions
JP2010520285A (ja) * 2007-03-08 2010-06-10 ゲンズイメ コーポレーション スルホンポリマー組成物
EP2152277A1 (en) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
EP2217215A1 (en) * 2007-12-14 2010-08-18 Genzyme Corporation Coated pharmaceutical compositions
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
ES2532210T3 (es) 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Métodos para el tratamiento concomitante de teofilina y febuxostat
LT3003327T (lt) 2013-06-05 2017-12-27 Tricida Inc. Protonus surišantys polimerai, skirti geriamajam vartojimui
CN113855703B (zh) 2014-12-10 2025-11-25 特里赛达公司 用于口服施用的质子结合聚合物
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
JP6792640B2 (ja) 2016-12-28 2020-11-25 富士フイルム株式会社 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法
EP3698799B1 (en) 2017-10-16 2022-01-26 FUJIFILM Corporation Hyperphosphatemia treatment agent
AU2018360867B2 (en) 2017-11-03 2024-12-12 Tricida, Inc. Compositions for and method of treating acid-base disorders
ES2980624T3 (es) * 2021-08-24 2024-10-02 Waterstone Pharmaceuticals Wuhan Co Ltd Polímeros, composiciones y métodos para tratar hiperuricemia
WO2023023938A1 (en) * 2021-08-24 2023-03-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271191A (en) * 1979-12-19 1981-06-02 Pierre Fabre S.A. Method of treating hyperuricemia and gout
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
CN1238789A (zh) * 1996-10-23 1999-12-15 陶氏化学公司 用于降低饮食中磷酸根或草酸根吸收的水溶性聚合物
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid

Similar Documents

Publication Publication Date Title
JP2004535384A5 (enExample)
JP2001521902A5 (enExample)
JP2008518949A5 (enExample)
JP2007517047A5 (enExample)
CA2444046A1 (en) Use of colesevelam in reducing serum glucose
JP2004516314A5 (enExample)
JP2008515556A5 (enExample)
JP2024119812A5 (enExample)
CA2206532A1 (en) Novel amidinonaphthyl derivative or salt thereof
CA2481365A1 (en) Occlusive composition comprising a poly (2-cyanoacrylate) monomer
JP2004531544A5 (enExample)
JP2005538035A5 (enExample)
JP2022548052A5 (enExample)
JP2004520473A5 (enExample)
JP2005508436A5 (enExample)
JP2009502355A5 (enExample)
JP2010511721A5 (enExample)
JP2001526218A5 (enExample)
JP2019211764A5 (enExample)
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
DE69912547D1 (de) Klebemassen für den Dentalbereich
CA2430857A1 (en) Percutaneous absorption-type pharmaceutical preparation and process for producing the same
JP2007537301A5 (enExample)
JP2020518685A5 (enExample)
CA2306214C (en) Plaster for topical use containing heparin and diclofenac